<a href="https://news.google.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?oc=5" target="_blank">CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026</a>&nbsp;&nbsp;<font color="#6f6f6f">The Manila Times</font>